Pediatric Gastroenterology, Hepatology & Nutrition

The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition (대한소아소화기영양학회)
권호 표지
DOI QR코드

DOI QR Code

Recommendations of Pharmacological Treatment in Childhood and Adolescents Obesity

소아, 청소년 비만 약물 치료의 올바른 이해

  • Jeong, Su Jin (Department of Pediatrics, College of Medicine CHA University, Bundang CHA General Hospital)
  • 정수진 (차의과학대학교 분당차병원 소아청소년과학교실)
  • Received : 2009.10.31
  • Accepted : 2009.11.06
  • Published : 20091100
Download PDF
⟨ Previous Next ⟩

Abstract

The incidence of childhood obesity has increased dramatically. Childhood obesity is an increasing health problem because of its strong associations with chronic health problems in children and adults. These health problems significantly contribute to the development of common chronic diseases in later life, including hypertension, type2 diabetes, hyperinsulinemia, coronary heart disease, and other psychological disorders. So it is an important issue to prevent and treat obesity during childhood and adolescent. Diet and exercise are the cornerstones of treatment for obesity and related complications. For obese children, some clinical trials have shown improvement with diet, exercise, and /or behavioral interventions. Promising interventions for high-risk individuals, such as bariatric surgery and novel pharmacological agents, also require rigorous assessment with attention to long-term patient important outcomes. There are various pharmacological approaches to the treatment of obesity in the adolescent population some of which have FDA approval. In the article we discuss pharmacological approaches to guide the treatment of obesity in the pediatric population, including risks of treatment, monitoring of potential side effects.

Keywords

References

  1. Schwimmer NB, Burwinkle TM, Varni JW. Health related quality of life of severly obese children and adolescent JAMA 2003;289:1813-9. https://doi.org/10.1001/jama.289.14.1813
  2. Must A, Jadaues PF, Dallal GE, Bajerma CJ. Long term morbidity and mortality of overweight adolescents: a follow up of the Harvard Growth Study of 1922 to 1935 N. Engl J Med 1997;327:1350-5.
  3. Whitakr RC, Wright JA, Pepe MS, Seidel KD, Diets WH. Predicting obesity in young adulthood from childhood and parental obesity. N Engl J Med 1997;337:869-73. https://doi.org/10.1056/NEJM199709253371301
  4. Fontaine KR, Redden DT, Wang C, Westfall AO, Allison DB. Years of life lost due to obesity JAMA 2003 Jan 8;289:187-93. https://doi.org/10.1001/jama.289.2.187
  5. Schwimmner JB. Managing overweight in older children and adolescents. Pediatr Ann 2004;33:39-44.
  6. Barlow SE, Dietz WH. Obesity evaluation and treatment: Expert Committee recommendations. The Maternal and Child Health Bureau, Health Resources and Services Administration and the Department of Health and Human Services. Pediatrics 1998 Sep;102:E29. https://doi.org/10.1542/peds.102.3.e29
  7. Epstein LH, Valoski AM, Kalarchian MA, McCurley J. Do children lose and maintain weight easier than adults: a comparison of child and parent weight changes from six months to ten years. Obes Res 1995;3:411-7. https://doi.org/10.1002/j.1550-8528.1995.tb00170.x
  8. Epstein LH, Valoski A, Wing RR, McCurley J. Ten year outcomes of behavioral family based treatment for childhood obsesity. Health Psychol 1994;13:373-83.
  9. National Task Force on the Prevention and Treatment of Obesity: Long term pharmacotherapy in the management of obesity. JAMA 1996;276:1907-15. https://doi.org/10.1001/jama.1996.03540230057036
  10. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimnogant. Lancet 2007;369: 71-7. https://doi.org/10.1016/S0140-6736(07)60033-6
  11. Yanovski SJ, Yanovski JA. Obesity. N Engl J 2002;346: 591-602. https://doi.org/10.1056/NEJMra012586
  12. WHO Western Pacific Region, International Association for the Study of Obesity, International Obesity Task Force: The Asia Pacific Perspective: Redefining Obesity and Its Treatment. Health Communications Australia, 2000.
  13. 대한 비만학회편. 비만치료 지침 2003.
  14. McGovern L, Johnson JN, Paulo R, Hettinger A, Singhal V, Kamath C, et al. Clinical review: treatment of pediatric obesity: a systematic review and meta-analysis of randomized trials. J Clin Endocrinol Metab 2008;93:4600-5. https://doi.org/10.1210/jc.2006-2409
  15. Uli N, Sundararajan S, Cuttler L. Treatment of childhood obesity. Curr Opin Endoc 2008;15:37-47. https://doi.org/10.1097/MED.0b013e3282f41d6a
  16. García-Morales LM, Berber A, Lucio-Ortiz C, Del-Rio- Navarro BE. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebocontrolled, parallel-group trial. Clin Ther 2006;28:770-82. https://doi.org/10.1016/j.clinthera.2006.05.008
  17. Hensrud DD. Pharmacotherapy for obesity. Med Clin North Am 2000;84:463-76. https://doi.org/10.1016/S0025-7125(05)70231-5
  18. Daniels SR, Long B, Crow S, Styne D, Sothern M, Vargas-Rodriguez I, Harris L, Walch J, Jasinsky O, Cwik K, Hewkin A, Blakesley V; Sibutramine Adolescent Study Group. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double-blind, placebo-controlled study. Pediatrics 2007; 120:e147-57. https://doi.org/10.1542/peds.2006-2137
  19. Berkowitz RI, Wadden TA, Taeshakovec Am, Cronquist JL. Behavior therapy and sibutramine for the treatment of adolescent obesity. JAMA 2003;289:1805-12. https://doi.org/10.1001/jama.289.14.1805
  20. Berkowitz RI, Fujioka K, Daniels SR, Hoppin AG, Owen S, Perry AC, Sothern MS, Renz CL, Pirner MA, Walch JK, Jasinsky O, Hewkin AC, Blakesley VA; Sibutramine Adolescent Study Group. Effects of sibutramine treatment in obese adolescents: a randomized trial. Ann Intern Med 2006;145:81-90. https://doi.org/10.7326/0003-4819-145-2-200607180-00005
  21. Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J. Effect of orlistat on weight and body composition in obese adolescents. JAMA 2005;293:2873-83. https://doi.org/10.1001/jama.293.23.2873
  22. Scheen AJ. Info-congress. Prevention of type 2 diabetes in obese patients: first results with orlistat in the XENDOS study Rev Med Liege 2002;57:617-21.
  23. Halpern A, Mancini MC. Treatment of obesity: an update on anti-obesity medications. Obes Rev 2003;4:25-42. https://doi.org/10.1046/j.1467-789X.2003.00083.x
  24. Foxcroft DR, Milne R. Orlistat for the treatment of obesity: rapid review and cost- effectiveness model. Obes Rev 2000;1:121-6. https://doi.org/10.1046/j.1467-789x.2000.00011.x
  25. DeFronzo RA, Goodman AM, Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:541-9. https://doi.org/10.1056/NEJM199508313330902
  26. Fontbonne A, Charles MA, Juhan-Vague I, Bard JM, Andre P, Isnard F, et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. Diabetes Care 1996; 19:920-6. https://doi.org/10.2337/diacare.19.9.920
  27. Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001;107:763.
  28. Burgert TS, Duran EJ, Goldberg-Gell R, Dziura J, Yeckel CW, Katz S, et al. Short-term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance. Pediatr Diabetes 2008;9:567-76. https://doi.org/10.1111/j.1399-5448.2008.00434.x
  29. Kwiterovich PO Jr. Recognition and management of dyslipidemia in children and adolescents. J Clin Endocrinol Metab 2008;93:4200-9. https://doi.org/10.1210/jc.2008-1270
  30. Shamir R, Feig JE, Fisher EA. Therapeutic approach to childhood hypercholesterolemia. Pediatr Endocrinol Rev. 2007;5:649-55.
  31. 서정기. 전신질환에 따른 간장애; 비만-지방간. 소화기학 336-7.
  32. Hookman P, Barkin JS. Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach. Am J Gastroenterol 2003;98:2093-7.
  33. Nobili V, Manco M, Ciampalini P, Alisi A, Devito R, Bugianesi E, et al. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study. Clin Ther 2008;30:1168-76. https://doi.org/10.1016/j.clinthera.2008.06.012
  34. Nobili V, Manco M, Devito R, Ciampalini P, Piemonte F, Marcellini M. Effect of vitamin E on aminotransferase levels and insulin resistance in children with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2006;24:1553-61. https://doi.org/10.1111/j.1365-2036.2006.03161.x
  35. Preuss HG, Rao CV, Garis R, Bramble JD, Ohia SE, Bagchi M, et al. An overview of the safety and efficacy of a novel, natural(󰠏)-hydroxycitric acid extract (HCASX) for weight management. J Med 2004;35:33-48.
  36. Mattes RD, Bormann L. Effects of (-)-hydroxycitric acid on appetitive variables. Physiol Behav. 2000;71:87-94. https://doi.org/10.1016/S0031-9384(00)00321-8
  37. Greenway FL, De Jonge L, Blanchard D, Frisard M, Smith SR. Effect of a dietary herbal supplement containing caffeine and ephedra on weight, metabolic rate, and body composition. Obes Res 2004;12:1152-7. https://doi.org/10.1038/oby.2004.144
  38. Haller CA, Jacob P 3rd, Benowitz NL. Enhanced stimulant and metabolic effects of combined ephedrine and caffeine. Clin Pharmacol Ther 2004;75:259-73. https://doi.org/10.1016/j.clpt.2003.11.375
  39. Westerterp-Plantenga MS, Lejeune MP, Kovacs EM. Body weight loss and weight maintenance in relation to habitual caffeine intake and green tea supplementation. Obes Res 2005;13:1195-204. https://doi.org/10.1038/oby.2005.142
  40. Dulloo G, Duret C, Rohrer D, Girardier L, Mensi N, Fathi M. Efficacy of a green tea extract rich in catechin polyphenoland caffeine in increasing 24h energy expenditure and fat oxidation in humans. Am J Clin Nutr 1999;70: 1040-5.
  41. Tapola NS, Lyyra ML, Kolehmainen RM, Sarkkinen ES, Schauss AG. Safety aspects and cholesterol-lowering efficacy of chitosan tablets. J Am Coll Nutr 2008;27:22- 30.